JP2021512608A5 - - Google Patents

Info

Publication number
JP2021512608A5
JP2021512608A5 JP2020542161A JP2020542161A JP2021512608A5 JP 2021512608 A5 JP2021512608 A5 JP 2021512608A5 JP 2020542161 A JP2020542161 A JP 2020542161A JP 2020542161 A JP2020542161 A JP 2020542161A JP 2021512608 A5 JP2021512608 A5 JP 2021512608A5
Authority
JP
Japan
Prior art keywords
extracellular vesicle
item
macrophage
macrophages
phenotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2020542161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512608A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/017731 external-priority patent/WO2019157535A1/en
Publication of JP2021512608A publication Critical patent/JP2021512608A/ja
Publication of JP2021512608A5 publication Critical patent/JP2021512608A5/ja
Priority to JP2024154757A priority Critical patent/JP2024166292A/ja
Ceased legal-status Critical Current

Links

JP2020542161A 2018-02-12 2019-02-12 マクロファージ分極のための方法及び組成物 Ceased JP2021512608A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024154757A JP2024166292A (ja) 2018-02-12 2024-09-09 マクロファージ分極のための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862629563P 2018-02-12 2018-02-12
US62/629,563 2018-02-12
PCT/US2019/017731 WO2019157535A1 (en) 2018-02-12 2019-02-12 Methods and compositions for macrophage polarization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024154757A Division JP2024166292A (ja) 2018-02-12 2024-09-09 マクロファージ分極のための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2021512608A JP2021512608A (ja) 2021-05-20
JP2021512608A5 true JP2021512608A5 (cg-RX-API-DMAC7.html) 2022-02-22

Family

ID=65729420

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542161A Ceased JP2021512608A (ja) 2018-02-12 2019-02-12 マクロファージ分極のための方法及び組成物
JP2024154757A Pending JP2024166292A (ja) 2018-02-12 2024-09-09 マクロファージ分極のための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024154757A Pending JP2024166292A (ja) 2018-02-12 2024-09-09 マクロファージ分極のための方法及び組成物

Country Status (17)

Country Link
US (2) US11512315B2 (cg-RX-API-DMAC7.html)
EP (2) EP3752615B1 (cg-RX-API-DMAC7.html)
JP (2) JP2021512608A (cg-RX-API-DMAC7.html)
KR (1) KR20200120624A (cg-RX-API-DMAC7.html)
CN (2) CN119614501A (cg-RX-API-DMAC7.html)
AU (1) AU2019218991A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020016228A2 (cg-RX-API-DMAC7.html)
CA (1) CA3088009A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002053A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020009694A2 (cg-RX-API-DMAC7.html)
EA (1) EA202091486A1 (cg-RX-API-DMAC7.html)
IL (1) IL276409A (cg-RX-API-DMAC7.html)
MX (1) MX2020008103A (cg-RX-API-DMAC7.html)
PH (1) PH12020551195A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006021SA (cg-RX-API-DMAC7.html)
TW (1) TW202003846A (cg-RX-API-DMAC7.html)
WO (1) WO2019157535A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3752615B1 (en) 2018-02-12 2025-08-27 Lonza Sales AG Methods and compositions for macrophage polarization
CA3095134A1 (en) 2018-03-28 2019-10-03 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in dna isolated from exosomes
US12312584B2 (en) 2018-10-02 2025-05-27 Exosome Therapeutics, Inc. cGMP exosome loaded therapeutics for treating sickle cell disease
WO2020106772A1 (en) * 2018-11-19 2020-05-28 Exosome Therapeutics, Inc. Exosome loaded therapeutics for the treatment of non-alcoholic steatohepatitis, diabetes mellitus type 1 and type 2, atherosclerotic cardiovascular disease, and alpha 1 antitrypsin deficiency
CN114729356A (zh) * 2019-08-14 2022-07-08 科迪亚克生物科学公司 靶向stat6的细胞外囊泡-aso构建体
CN114729327A (zh) * 2019-08-14 2022-07-08 科迪亚克生物科学公司 具有stat3反义寡核苷酸的细胞外囊泡
CN120771302A (zh) * 2019-08-14 2025-10-14 隆萨销售股份公司 与分子连接的细胞外囊泡及其用途
EP4013872A1 (en) * 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicles with antisense oligonucleotides targeting kras
EP4013878A1 (en) * 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicle-aso constructs targeting cebp/beta
CN114727947A (zh) * 2019-09-25 2022-07-08 科迪亚克生物科学公司 细胞外囊泡组合物
US20230013636A1 (en) * 2019-12-05 2023-01-19 Board Of Regents, The University Of Texas System Exosomes-based therapy for liver fibrosis and other diseases with fibrosis
US12697307B2 (en) 2020-05-11 2026-08-04 Strm.Bio Incorporated Compositions and methods related to megakaryocyte-derived extracellular vesicles
WO2021237100A1 (en) * 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
CN111748523B (zh) * 2020-07-17 2022-11-22 南通大学 一种免疫调节小胞外囊泡的制备方法及其用途
WO2022076596A1 (en) * 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
WO2022087505A1 (en) 2020-10-23 2022-04-28 Strm.Bio Incorporated Compositions and methods related to megakaryocyte-derived extracellular vesicles for treating myeloproliferative neoplasms
AU2021368746A1 (en) * 2020-10-30 2023-06-01 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Stat-activated macrophages, compositions, and uses thereof
US20240093191A1 (en) * 2021-02-03 2024-03-21 Research Institute At Nationwide Children's Hospital Compositions and methods for treating disease associated with dux4 overexpression
AU2022264498A1 (en) 2021-04-26 2023-09-28 Strm.Bio Incorporated Compositions and methods related to megakaryocyte-derived extracellular vesicles for fanconi anemia
CN113262305B (zh) * 2021-05-27 2022-03-25 浙江大学 Coro1a基因作为靶点在制备抗肿瘤药物中的应用
CN115429896A (zh) * 2021-05-31 2022-12-06 复旦大学 一种肿瘤相关巨噬细胞代谢调节和肿瘤杀伤协同作用的细菌外泌囊泡
CA3223475A1 (en) 2021-07-02 2023-01-05 Spark Biopharma, Inc Novel benzopyran derivative and use thereof
CN113521252B (zh) * 2021-07-29 2022-12-20 南开大学 Tnfsf15蛋白作为巨噬细胞免疫增强剂的用途及其活化方法
WO2023034537A1 (en) * 2021-09-02 2023-03-09 Molecular Axiom, Llc Compositions and methods for modulating kras expression
EP4419686A4 (en) * 2021-10-21 2025-10-15 Nanothera Biosciences Inc COMPOSITIONS AND METHODS OF EXTINGUISHING KRAS
CN114058621B (zh) * 2021-12-03 2023-06-16 温州医科大学 一种lncRNA基因修饰细胞分泌的外泌体及应用
CN114209814B (zh) * 2021-12-15 2024-02-23 南开大学 Tnfsf15蛋白在促进骨髓干细胞分化为巨噬细胞并扩增中的用途
CN114561347A (zh) * 2022-02-25 2022-05-31 和携科技有限公司 一种脂肪间充质干细胞的培养基和培养方法
CN115948496A (zh) * 2022-04-15 2023-04-11 健艾仕生物医药科技(杭州)有限公司 一种巨噬细胞极化过程高通量检测的方法及应用
CN115137708B (zh) * 2022-06-24 2023-05-16 重庆医科大学 装载yap1核酸序列的肝纤维化靶向纳米颗粒及其制备方法和应用
US20240024491A1 (en) * 2022-07-13 2024-01-25 Navidea Biopharmaceuticals, Inc. Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cells
CN115261410A (zh) * 2022-07-20 2022-11-01 中山大学 一种基因编辑工程化m1型巨噬细胞外泌体的制备方法及其应用
WO2024044788A2 (en) * 2022-08-26 2024-02-29 Georgia State University Research Foundation, Inc. Treating chronic inflammation and cancer by macrophage polarization
CN115814108B (zh) * 2022-12-27 2025-04-25 华中科技大学 一种用于个性化肿瘤治疗的工程化巨噬细胞载药微颗粒制剂及其制备方法
CN116370647B (zh) * 2023-04-11 2025-07-11 吉林大学 一种用于胰腺癌免疫治疗的工程化外泌体及制备方法
CN119215144B (zh) * 2023-09-08 2025-08-08 首都医科大学附属北京朝阳医院 Lrg1在制备促进巨噬细胞向m1型分化的药物中的应用和巨噬细胞激活剂
KR102635831B1 (ko) * 2023-11-01 2024-02-13 강원대학교 산학협력단 Cxcl11에 의한 m2 대식세포의 재분극 유도를 통한 폐섬유화증 치료 용도

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517644B1 (en) * 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
GB2382408B (en) * 2000-06-19 2004-06-02 Halliburton Energy Systems Inc Apparatus and methods for applying time lapse VSP to monitor a reservoir
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US20040115634A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals, Inc. Modulation of stat 6 expression
DE102004026309A1 (de) * 2004-05-26 2005-12-29 Haarlems Allergenen Laboratorium B.V. Pharamzeutische Zusammensetzung zur Behandlung allergischer Erkrankungen, pathologischer Atemswegsveränderungen und von Krebs durch Modulation der Genexpression des Stat6
DE102006050655A1 (de) * 2006-10-24 2008-04-30 Halmon Beheer B.V. Pharmazeutische Zusammensetzung zur Behandlung allergischer Erkrankungen
JP6010458B2 (ja) * 2009-04-03 2016-10-19 ダイセルナ ファーマシューティカルズ, インコーポレイテッドDicerna Pharmaceuticals, Inc. 非対称二本鎖rnaによる特異的阻害のための、方法および組成物
WO2010115202A2 (en) * 2009-04-03 2010-10-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
JP2014507160A (ja) * 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス.アー.エール.エル. 循環バイオマーカー
CA2892490A1 (en) 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
WO2015058148A1 (en) * 2013-10-17 2015-04-23 Children's Hospital Los Angeles Antibody dependent exosome therapy
US20160346334A1 (en) * 2014-02-05 2016-12-01 Stc.Unm Exosomes as a therapeutic for cancer
DK3209778T3 (da) * 2014-10-24 2019-05-27 Astrazeneca Kombination
EA201890006A1 (ru) * 2015-06-10 2018-05-31 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Применение экзосом для лечения болезни
GB201516801D0 (en) * 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof
HK1251624A1 (zh) 2015-09-24 2019-02-01 Ionis Pharmaceuticals, Inc. Kras表达的调节剂
SG10202008883SA (en) 2016-03-15 2020-10-29 Codiak Biosciences Inc Therapeutic membrane vesicles
EP3500244B1 (en) 2016-08-22 2026-07-08 Lonza Sales AG Methods of suppressing delivery of exosomes to liver and spleen
KR20240033086A (ko) 2017-08-25 2024-03-12 코디악 바이오사이언시즈, 인크. 막 단백질을 사용한 치료용 엑소좀의 제조
EP3752615B1 (en) 2018-02-12 2025-08-27 Lonza Sales AG Methods and compositions for macrophage polarization
CN120771302A (zh) * 2019-08-14 2025-10-14 隆萨销售股份公司 与分子连接的细胞外囊泡及其用途
US20210322405A1 (en) * 2020-04-15 2021-10-21 Washington University Compositions and methods for treating cancer
KR20240158272A (ko) * 2022-03-04 2024-11-04 아이-맵 바이오파마 유에스 리미티드 암 치료를 위한 kras 억제제를 포함하는 조합 요법

Similar Documents

Publication Publication Date Title
Wang et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance
Kieran et al. Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma
Jarosz-Biej et al. M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma
US20230365971A1 (en) Methods and compositions for macrophage polarization
US12383575B2 (en) Polyinosinic—polycytidylic acid compositions
CN104427992B (zh) 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法
JP2021529753A5 (cg-RX-API-DMAC7.html)
JP2002517434A (ja) 免疫系を刺激する方法
US11680266B2 (en) Endomucin inhibitor as an anti-angiogenic agent
CN116829583A (zh) 延长健康期限和治疗年龄相关疾病的方法
Liu et al. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
JP2024020338A (ja) 白斑を処置するための方法及び組成物
EP3942097A1 (en) Chmp2a as a regulator of natural killer cell-mediated activity
JP2019534322A (ja) Tim−3の上昇を処置する方法
EP4739707A1 (en) Il-1ra blockers for treatment and prevention of sepsis
TH2001004404A (th) วิธีการและองค์ประกอบสำหรับการโพลาไรเซชันมาโครฟาจ
KR102561720B1 (ko) 종양에 대한 직접적인 억제 효과를 갖는 인터페론의 결정 방법 및 그 용도
WO2023080157A1 (ja) Htlv-1関連脊髄症(ham)の治療又は予防剤、並びに、hamの治療有効性判定方法、活動性評価方法又は診断方法
JP2023552674A (ja) がん治療のためのマイコバクテリア免疫療法
WO2022109022A1 (en) Rna-targeting splicing modifiers for treatment of mda5-associated conditions and diseases
Bilicki et al. Glioblastoma-actual knowledge and future perspectives
WO2017085566A1 (en) Methods and compositions for increase/induction of immune responses
HK40121253A (en) Aptamers, pharmaceutical compositions thereof, and methods for preventing or treating bcma-associated diseases or conditions
CN117460526A (zh) 用于治疗癌症的分枝杆菌免疫疗法
WO2026107366A1 (en) Targeting il1r1, meox1, and maff for treatment of inflammatory bowel disease